MedTrace Logo

Melatonin for Prevention of Metabolic Side Effects of Olanzapine

NCT01593774 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 36

Last updated 2013-04-09

No results posted yet for this study

Summary

The purpose of this study is to determine whether melatonin can prevent metabolic side effects of olanzapine such as weight gain, elevated glucose concentrations and lipid abnormalities.

Conditions

Interventions

DRUG

Melatonin

Tablet melatonin 3 mg/day at 9 pm as intervention group

DRUG

Placebo

Placebo (with the same shape and taste as melatonin) at 9 pm as control group

Sponsors & Collaborators

  • Guilan University of Medical Sciences

    lead OTHER

Principal Investigators

  • Mohammad Jafar Modabbernia, MD · Guilan University of Medical Sciences

Study Design

Allocation
RANDOMIZED
Purpose
PREVENTION
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
65 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2012-05-31
Primary Completion
2013-03-31
Completion
2013-03-31

Countries

  • Iran

Study Locations

More Related Trials

Entities

Drugs
Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01593774 on ClinicalTrials.gov